List view / Grid view
Opdivo and Yervoy displayed a 23 percent survival rate at three years compared to 15 percent with chemotherapy, Phase III trial shows.
The European Commission approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for certain metastatic colorectal cancers after a trial found the combination meaningfully improved response rates.
The ability to precisely direct powerful therapeutics not only makes treatments more effective, but also prevents debilitating side effects. Here, Dave Elder and Stacey Treichler highlight the great potential of antibody-drug conjugates (ADCs) for improved treatment of oncology indications and beyond.
The combination was approved on Phase III trial results which show it doubled progression-free survival and reduced risk of death by 40 percent, compared to standard of care.
The European Commission has approved Opdivo (nivolumab) to treat oesophageal squamous cell carcinoma after studies showed its clinical benefits compared to chemotherapy alone.
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
Sales of Merck’s drug Keytruda have grown beyond those of Bristol-Myers Squibb’s Opdivo, to become the global leading PD-1 inhibitor.
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Adjuvant nivolumab has been found to be more superior than ipilimumab in the standard of care in patients with surgically resected stage III/IV melanoma...
Alternative immunotherapy drug nivolumab is more effective than current standard of care in treating advanced melanoma after surgical removal of disease.
7 June 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist...